{"schema_version":"secwatch.filing_event.v1","accession":"0001831283-22-000082","form_type":"8-K","ticker":"LIANY","cik":"0001831283","company_name":"LianBio","filed_at":"2022-12-19T23:59:59+00:00","discovered_at":"2026-05-14T18:03:52.498639+00:00","generated_at":"2026-06-21T02:43:17.029007+00:00","sec_items":["1.01","7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Pfizer opts into LianBio's RSV drug sisunatovir rights in China & Singapore; $20M upfront, up to $135M milestones","bullets":["$20M upfront payment from previously restricted cash paid by Pfizer in 2020 under the existing strategic collaboration.","Up to $135M in potential development and commercial milestone payments plus tiered low single-digit percent of net sales.","Pfizer assumes all development/commercial costs in the region and releases LianBio from its royalty and milestone obligations to ReViral.","LianBio expects the transaction to extend cash runway through end of 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001831283-22-000082","json":"https://secwatch.observer/filing/0001831283-22-000082.json","markdown":"https://secwatch.observer/filing/0001831283-22-000082.md","text":"https://secwatch.observer/filing/0001831283-22-000082.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1831283/000183128322000082/0001831283-22-000082-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1831283/000183128322000082/lian-20221216.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T02:43:17.029007+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f10a071a3c81bcc180b4d88c054a9c6be581aa7e","claim":"LianBio entered into Commercial Agreement with Pfizer Inc. and ReViral Ltd. valued at $20 million upfront payment, up to $135 million in potential milestones (effective 2022-12-16).","evidence_excerpt":"On December 16, 2022, LianBio Development HK Limited and LianBio Respiratory Limited, each a wholly-owned subsidiary of LianBio (the “Company,” and collectively with LianBio Development HK Limited and LianBio Respiratory Limited, “LianBio”), Pfizer Inc. (“Pfizer”) and ReViral Ltd. (“ReViral,” now a wholly-owned subsidiary of Pfizer) entered into a commercial agreement (the “Commercial Agreement”) with respect to sisunatovir (a fusion inhibitor product for treatment of respiratory syncytial virus (or RSV)) as the first Opted-in Product under the Strategic Collaboration Agreement dated November 17, 2020 by and between the Company and Pfizer (the “Collaboration Agreement”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1831283/000183128322000082/0001831283-22-000082-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"asset purchase"},{"label":"Counterparty","value":"Pfizer Inc. and ReViral Ltd."},{"label":"Value","value":"$20 million upfront payment, up to $135 million in potential milestones"},{"label":"Effective","value":"2022-12-16"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}